The Role of Steroids Following Selective Laser Trabeculoplasty

The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00406042

Enrollment

Registered

2006-12-04

Start date

2005-09-30

Completion date

2006-06-30

Last updated

2007-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

glaucoma, trabeculoplasty, steroids

Brief summary

To evaluate whether or not using topical steroids after selective laser trabeculoplasty affects intraocular pressure outcomes.

Detailed description

Subjects undergoing bilateral SLT will be randomly assigned to use prednisolone acetate 1% in one eye four times daily with no treatment in the fellow eye, for one week following SLT. Examinations will occur at baseline, and one week, one month and three months after SLT. IOP and anterior chamber inflammation will be noted at each visit.

Interventions

DRUGprednisolone acetate 1%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* glaucoma or ocular hypertension * need for bilateral SLT

Exclusion criteria

* eye disease precluding accurate IOP measurement * contraindication to topical prednisolone acetate

Design outcomes

Primary

Measure	Time frame
Intraocular pressure reduction	—

Secondary

Measure	Time frame
Anterior chamber inflammation	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026